[Von Willebrand disease--from biochemistry to clinical practice].
Sveinsdottir
Signy Vala
SV
Skånes universitetssjukhus, Malmö. Signy.Sveinsdottir@skane.se
Hillarp
Andreas
A
Astermark
Jan
J
Svensson
Peter J
PJ
Berntorp
Erik
E
D000368:Aged; D000933:Antifibrinolytic Agents / Q000627:therapeutic use; D003894:Deamino Arginine Vasopressin / Q000627:therapeutic use; D005260:Female; D006490:Hemostatics / Q000627:therapeutic use; D006801:Humans; D008297:Male; D008875:Middle Aged; D014148:Tranexamic Acid / Q000627:therapeutic use; D056725:von Willebrand Disease, Type 1 / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D056728:von Willebrand Disease, Type 2 / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D056729:von Willebrand Disease, Type 3 / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics; D014842:von Willebrand Diseases / Q000175:diagnosis / Q000188:drug therapy / Q000235:genetics
D000933:Antifibrinolytic Agents; D006490:Hemostatics; D014148:Tranexamic Acid; D003894:Deamino Arginine Vasopressin